Background/Aims: Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease (AD). In this study, we used a voxel-based specific regional analysis system for AD (VSRAD) to analyze the hippocampal volume and to assess the pharmacologic effects of donepezil as a disease modifier. Methods: A total of 185 AD patients underwent MRI, 120 (43 men and 77 women, 77.8 ± 7.1 years) without and 65 (29 men and 36 women, 78.4 ± 6.0 years) with donepezil treatment. VSRAD was compared in both groups and against a database of 80 normal subjects. The Z-score was used to assess the degree of hippocampal atrophy. Results: No significant difference between the groups was found for age, sex, or Z-scores, but a significant difference was found for mean Mini-Mental State Examination (MMSE) scores (p = 0.02, Student's t test). Single regression analysis showed no significant association between Z-scores and MMSE scores in the treated group (p = 0.494), but a significant association in the untreated group (p = 0.001) was observed. This implies that the MMSE score becomes lower when the Z-score is higher in the untreated group, whereas there is no significant trend in the treated group. Conclusion: Donepezil affects the relationship between hippocampal volume and cognitive function and may therefore have a pharmacologic effect as a disease modifier.

1.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
2.
Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
3.
Coyle JT, Price DL, DeLong MR: Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
4.
Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000;11:299-313.
5.
Meunier J, Ieni J, Maurice T: The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006;149:998-1012.
6.
Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A: Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003;306:772-777.
7.
Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E: Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162:676-682.
8.
Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160:2003-2011.
9.
Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG: MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992;42:183-188.
10.
Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F: Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993;50:949-954.
11.
Matsuda H, Mizumura S, Nemoto K, Yamashita F, Imabayashi E, Sato N, Asada T: Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer disease. AJNR Am J Neuroradiol 2012;33:1109-1114.
12.
Mrzilkova J, Zach P, Bartos A, Tintera J, Ripova D: Volumetric analysis of the pons, cerebellum and hippocampi in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:224-234.
13.
Hayashi H, Kawakatsu S, Suzuki A, Shibuya Y, Kobayashi R, Sato C, Otani K: Application of the VSRAD, a specific and sensitive voxel-based morphometry, to comparison of entorhinal cortex atrophy between dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:328-331.
14.
Matsuda H: Voxel-based morphometry of brain MRI in normal aging and Alzheimer's disease. Aging Dis 2013;4:29-37.
15.
Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, Morris JC: Correlations between antemortem hippocampal volume and postmortem neuropathology in ad subjects. Alzheimer Dis Assoc Disord 2004;18:190-195.
16.
Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL: The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex 2009;19:497-510.
17.
Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA: Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002;58:1476-1482.
18.
Jack CR Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC: Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-757.
19.
Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, Sexton G, Kaye JA: Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003;61:487-492.
20.
Li X, Shimizu S, Jibiki I, Watanabe K, Kubota T: Correlations between z-scores of VSRAD and regional cerebral blood flow of SPECT in patients with Alzheimer's disease and mild cognitive impairment. Psychiatry Clin Neurosci 2010;64:284-292.
21.
Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA: Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
22.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
23.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24.
Fjell AM, Amlien IK, Westlye LT, Walhovd KB: Mini-mental state examination is sensitive to brain atrophy in Alzheimer's disease. Dement Geriatr Cogn Disord 2009;28:252-258.
25.
Hayashi T, Su TP: Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131:596-610.
26.
Bowen WD: Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 2000;74:211-218.
27.
Jansen KL, Faull RL, Storey P, Leslie RA: Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res 1993;623:299-302.
28.
Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K, Kawamura K, Sasaki T, Kobayashi S, Katayama Y, Ishiwata K: Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 2008;22:151-156.
29.
Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT: Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 2006;317:606-614.
30.
Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K: High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009;12:1127-1131.
31.
Ishiwata K, Kobayashi T, Kawamura K, Matsuno K: Age-related changes of the binding of [3h]SA4503 to sigma1 receptors in the rat brain. Ann Nucl Med 2003;17:73-77.
32.
Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, Ohba H, Harada N, Matsuno K, Ishii K, Ishiwata K: An increase of sigma receptors in the aged monkey brain. Neurobiol Aging 2003;24:745-752.
33.
Lobner D, Lipton P: Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci Lett 1990;117:169-174.
34.
Matsuno K, Kobayashi T, Tanaka MK, Mita S: Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996;312:267-271.
35.
Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, Oda K, Sasaki T, Sakayori O, Hamamoto M, Kobayashi S, Katayama Y: Function of sigma1 receptors in Parkinson's disease. Acta Neurol Scand 2005;112:103-107.
36.
Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB: Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.
37.
Ishima T, Nishimura T, Iyo M, Hashimoto K: Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1656-1659.
38.
Kotani S, Yamauchi T, Teramoto T, Ogura H: Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience 2006;142:505-514.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.